Passage Bio (PASG) Competitors $0.40 +0.02 (+6.26%) As of 11:49 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PASG vs. FBRX, CLLS, CLYM, CABA, MCRB, TCRX, VNRX, SRZN, EPIX, and PLRXShould you be buying Passage Bio stock or one of its competitors? The main competitors of Passage Bio include Forte Biosciences (FBRX), Cellectis (CLLS), Climb Bio (CLYM), Cabaletta Bio (CABA), Seres Therapeutics (MCRB), TScan Therapeutics (TCRX), VolitionRx (VNRX), Surrozen (SRZN), ESSA Pharma (EPIX), and Pliant Therapeutics (PLRX). These companies are all part of the "pharmaceutical products" industry. Passage Bio vs. Its Competitors Forte Biosciences Cellectis Climb Bio Cabaletta Bio Seres Therapeutics TScan Therapeutics VolitionRx Surrozen ESSA Pharma Pliant Therapeutics Passage Bio (NASDAQ:PASG) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment. Do insiders and institutionals have more ownership in PASG or FBRX? 53.5% of Passage Bio shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 4.3% of Passage Bio shares are owned by company insiders. Comparatively, 5.9% of Forte Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has more risk and volatility, PASG or FBRX? Passage Bio has a beta of 1.67, suggesting that its stock price is 67% more volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 2.97, suggesting that its stock price is 197% more volatile than the S&P 500. Is PASG or FBRX more profitable? Passage Bio's return on equity of -93.59% beat Forte Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Passage BioN/A -93.59% -59.65% Forte Biosciences N/A -149.15%-114.25% Which has stronger earnings & valuation, PASG or FBRX? Forte Biosciences is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPassage BioN/AN/A-$64.77M-$1.02-0.40Forte BiosciencesN/AN/A-$35.48M-$16.29-0.80 Do analysts prefer PASG or FBRX? Passage Bio presently has a consensus price target of $7.50, indicating a potential upside of 1,756.44%. Forte Biosciences has a consensus price target of $61.00, indicating a potential upside of 367.43%. Given Passage Bio's higher probable upside, analysts clearly believe Passage Bio is more favorable than Forte Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Passage Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Forte Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to PASG or FBRX? In the previous week, Passage Bio and Passage Bio both had 8 articles in the media. Forte Biosciences' average media sentiment score of 0.44 beat Passage Bio's score of -0.14 indicating that Forte Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Passage Bio 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Forte Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryPassage Bio beats Forte Biosciences on 6 of the 11 factors compared between the two stocks. Get Passage Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for PASG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PASG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PASG vs. The Competition Export to ExcelMetricPassage BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$25.11M$2.89B$5.49B$8.92BDividend YieldN/A2.69%5.38%4.12%P/E Ratio-0.4021.3826.2019.83Price / SalesN/A277.62404.03113.43Price / CashN/A41.8936.4957.06Price / Book0.417.347.985.35Net Income-$64.77M-$55.05M$3.15B$248.34M7 Day Performance23.93%1.69%1.48%2.40%1 Month Performance-7.38%6.28%4.33%5.39%1 Year Performance-59.58%4.67%35.36%19.53% Passage Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PASGPassage Bio2.8744 of 5 stars$0.40+6.3%$7.50+1,756.4%-57.0%$25.11MN/A-0.40130News CoverageFBRXForte Biosciences3.0587 of 5 stars$12.93+5.6%$61.00+371.8%+56,859.7%$80.65MN/A0.005CLLSCellectis3.0072 of 5 stars$1.53+5.2%$4.00+162.3%-19.9%$80.60M$49.22M-1.77290CLYMClimb Bio3.7045 of 5 stars$1.24+5.1%$9.00+625.8%N/A$79.74MN/A0.009News CoveragePositive NewsCABACabaletta Bio2.2833 of 5 stars$1.52-3.2%$14.43+849.2%-80.0%$79.67MN/A0.0050Positive NewsGap UpMCRBSeres Therapeutics3.6187 of 5 stars$11.11+22.1%$73.67+563.1%-25.9%$79.46M$126.32M-2.42330Positive NewsHigh Trading VolumeTCRXTScan Therapeutics2.9056 of 5 stars$1.45+3.6%$7.80+437.9%-75.9%$79.23M$2.82M0.00100Gap DownVNRXVolitionRx1.6355 of 5 stars$0.76-9.3%$3.50+360.5%+23.9%$78.30M$1.31M-2.1180Gap DownSRZNSurrozen2.9589 of 5 stars$8.94-0.9%$38.50+330.6%-17.7%$77.24M$10.65M0.0080News CoverageHigh Trading VolumeEPIXESSA Pharma1.9735 of 5 stars$1.70-1.7%$2.00+17.6%-66.2%$76.79MN/A-2.7050PLRXPliant Therapeutics4.2303 of 5 stars$1.16-7.2%$13.31+1,047.6%-89.2%$76.73M$1.58M0.0090Gap UpHigh Trading Volume Related Companies and Tools Related Companies FBRX Alternatives CLLS Alternatives CLYM Alternatives CABA Alternatives MCRB Alternatives TCRX Alternatives VNRX Alternatives SRZN Alternatives EPIX Alternatives PLRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PASG) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Passage Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Passage Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
